RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC
The PD-1/VEGF bispecific antibody produced high response rates with chemotherapy across squamous and non-squamous lung cancer cohorts, supporting its advancement into Phase 3 development. RemeGen and AbbVie have reported strong early clinical results for…
Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…
Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
Hangzhou-based Unike Biopharma has completed an angel financing round worth tens of millions of RMB, giving the young biotech fresh capital to advance a broad pipeline of long-acting protein and peptide therapeutics built around its proprietary ZT…
1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
1cBio has struck a regional licensing deal with Hong Kong-based Lee’s Pharmaceutical Holdings to advance OC-3, its next-generation selective PARP1 inhibitor, across Greater China and parts of Southeast Asia. Under the agreement announced September 9,…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…
Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline
Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…
2026 Global XDC Innovation Conference
Explore the new frontiers of XDC fusion and breakthrough innovation – under the theme: Convergence & Innovation: The New Frontiers of Bioconjugation. Highlights Sneak Peek🔹 Focused Innovation Agenda – Key XDC technologies and emerging modalities,…
CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing
CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in…